BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38306303)

  • 1. Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer.
    Scully MA; Wilhelm R; Wilkins DE; Day ES
    ACS Biomater Sci Eng; 2024 Mar; 10(3):1355-1363. PubMed ID: 38306303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.
    Scully MA; Wilkins DE; Dang MN; Hoover EC; Aboeleneen SB; Day ES
    Mol Pharm; 2023 Aug; 20(8):3895-3913. PubMed ID: 37459272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt signaling in triple negative breast cancer is associated with metastasis.
    Dey N; Barwick BG; Moreno CS; Ordanic-Kodani M; Chen Z; Oprea-Ilies G; Tang W; Catzavelos C; Kerstann KF; Sledge GW; Abramovitz M; Bouzyk M; De P; Leyland-Jones BR
    BMC Cancer; 2013 Nov; 13():537. PubMed ID: 24209998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
    Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.
    Xu J; Prosperi JR; Choudhury N; Olopade OI; Goss KH
    PLoS One; 2015; 10(2):e0117097. PubMed ID: 25658419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer.
    Sun J; Li X; Yu E; Liu J; Sun L; He Q; Lu Q
    Diagn Pathol; 2021 May; 16(1):45. PubMed ID: 34006305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.
    Wang Z; Li Y; Xiao Y; Lin HP; Yang P; Humphries B; Gao T; Yang C
    Int J Cancer; 2019 Nov; 145(10):2767-2780. PubMed ID: 31008533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression.
    Lim JP; Nair S; Shyamasundar S; Chua PJ; Muniasamy U; Matsumoto K; Gunaratne J; Bay BH
    Cancer Lett; 2019 Jun; 452():119-131. PubMed ID: 30905819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
    Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
    Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
    J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
    BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.
    Dey N; Young B; Abramovitz M; Bouzyk M; Barwick B; De P; Leyland-Jones B
    PLoS One; 2013; 8(10):e77425. PubMed ID: 24143235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.
    Zhu S; Sun J; Liu X; Shao H; Feng C; Wang Z; Zheng X; Wei S
    Mol Cell Biol; 2022 Jun; 42(6):e0018821. PubMed ID: 35499320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
    Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
    PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
    Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
    J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.